Development of a Novel Synthetic Drug for Osteoporosis and Fracture Healing

Abstract

This 4-year study strongly supported salubrinals therapeutic action on the prevention of bone loss by elevating bone formation and inhibiting bone resorption. The observed dual role of salubrinal is unique, and currently no therapeutic drugs provide these dual functions. In the animal experiments for evaluating the effects of salubrinal on osteoporosis, osteonecrosis and bone fracture healing, salubrinal presented its anabolic and anti-catabolic effects. In in vitro experiments, the mechanisms of salubrinals action through genome-wide mRNA and micro RNA analyses revealed that salubrinal induces its unique functions through novel targets in bone remodeling, which are mediated by eukaryotic translation initiation factor 2 alpha (eIF2a) signaling. The U.S. patent for use of salubrinal in treatment of bone diseases was issued in 2015.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Nov 01, 2015
Accession Number
AD1011454

Entities

People

  • Hiroki Yokota

Organizations

  • Indiana University

Tags

DTIC Thesaurus Topics

  • Bone And Bones
  • Bone Diseases
  • Bone Fractures
  • Cells
  • Chemistry
  • Health Services
  • Lymphocytes
  • Medical Personnel
  • Orthopedics
  • Osteogenesis

Fields of Study

  • Biology

Readers

  • Immunology and Pathology